To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Liver Cancer

Conor Killmurray
The Food and Drug Administration granted an accelerated approval to the combination of Opdivo and Yervoy for the treatment of patients with advanced hepatocellular carcinoma who were previously treated with Nexavar.
Sponsored Content
Researchers hope the new PROOF trial will show that infigratinib, a targeted drug, will expand options in treating advanced cholangiocarcinoma. Patients are enrolling now.
Brian M. Wolpin, M.D., M.P.H.
A circulating cell-free DNA test for patients with gastrointestinal cancers has a 90% accuracy rate to detect patients’ cancers and could provide a standard test in the future, according to new study findings.
Peter Galle, M.D., Ph.D
The combination treatment of Tecentriq (atezolizumab) and Avastain (bevacizumab) improved patient-reported outcomes and quality of life in a recent phase 3 study.
Beth Fand Incollingo
Radiofrequency ablation was statistically on par with surgery when it came to survival after an early recurrence of liver cancer, but surgery provided more benefit if the disease was a bit more advanced.
Katie Kosko
Patients with hepatocellular carcinoma whose tumors couldn’t be surgically removed lived longer and experienced few side effects after stereotactic body radiotherapy, according to phase 2 study findings.
Kristie L. Kahl
The FDA has granted a priority review to a new drug application (NDA) for pemigatinib as a treatment for patients with previously treated, locally advanced or metastatic cholangiocarcinoma – a cancer that originates in the bile ducts – with FGFR2 fusions or rearrangements, according to Incyte, the agent’s manufacturer.
Jessica Skarzynski
While radiation therapy may be a common alternative for inoperable hepatocellular carcinoma, two new studies suggest that proton radiation therapy may offer the same benefits as the more traditionally used photon radiation therapy, with less toxicity.
Beth Fand Incollingo
Nearly one-quarter of inoperable intrahepatic cholangiocarcinomas shrank enough to make surgery possible after selective internal radiation was added to chemotherapy, a study shows.
Katie Kosko
Both men and women have seen an increase in liver cancer diagnoses and death over the past nearly 20 years, according to new study findings.

Sign In

Not a member? Sign up now!
Continue without login